|
Synonyms: ACE-910 | ACE910 | emicizumab-kxwh | Hemlibra® | RG6013
emicizumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Emicizumab, is a humanised bispecific antibody that binds blood coagulation factors IXa and X and acts as a factor VIII mimetic to bring about activation of factor X, and promote coagulation [2-3,5]. In essence, emicizumab works by bridging between coagulation factors IX and X and is the first-in-class drug for haemophilia A prevention with this mechanism of action.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. FDA (2017) | EMA (2018) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10115 | emicizumab |
| Synonyms |
| ACE-910 | ACE910 | emicizumab-kxwh | Hemlibra® | RG6013 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 564 |
| Other databases | |
| GtoPdb PubChem SID | 354702217 |
| Search PubMed clinical trials | emicizumab |
| Search PubMed titles | emicizumab |
| Search PubMed titles/abstracts | emicizumab |
